Continuous glucose monitors (CGMs) are no longer just diabetes devices. They are becoming health data streams that AI systems can scan for patterns, forecasts, and risk signals.
That shift is already moving CGM data into consumer wellness apps, clinical trials, and enterprise health technology. The strongest evidence supports short-term glucose forecasting; broader claims about diagnosing health status or profiling users from glucose patterns still need stronger validation.
The consumer market widened after the FDA cleared Dexcom’s Stelo in March 2024 as the first over-the-counter CGM for adults 18 and older who do not use insulin. Stelo is not for people with problematic hypoglycemia because it does not provide low-glucose warnings.
Dexcom added an AI layer later that year, saying in December 2024 that its GenAI platform would use Google Cloud’s Vertex AI and Gemini models to personalize Stelo weekly insights based on glucose, activity, and sleep data.
From glucose readings to AI forecasts
A clinic blood glucose test captures one value at one moment. A CGM captures a time series: how glucose rises after meals, falls after activity, changes overnight, or varies after poor sleep. That structure makes CGM data useful for sequence models, including LSTM and transformer systems used in glucose prediction research, but the model is only as reliable as the data pipeline feeding it.
Those models can use prior readings, rate of change, meals, activity, sleep, and medication context to forecast glucose changes, including dangerous lows.
In January 2026, a Nature paper introduced GluFormer, a foundation model trained on more than 10 million glucose measurements from 10,812 adults and tested across 19 external cohorts. The study found that CGM patterns could improve some metabolic risk predictions, but it remains research evidence, not a consumer diagnostic claim.
The limits of glucose-based inference
CGM data is not the same as direct blood glucose measurement. CGMs measure interstitial fluid glucose — glucose in the fluid between cells — which generally tracks blood glucose but can lag or vary in ways that affect predictions.
Product claims need that caveat. A model that works on clean research data may behave differently with sensor noise, inconsistent wear, missing meal logs, or underrepresented populations. In CGM AI, as in other enterprise AI projects, a data pipeline problem can look like a model problem.
Consumer wearables need a separate guardrail. The FDA warned in 2024 against smartwatches and smart rings that claim to measure glucose without piercing the skin. Smartwatch apps can still display readings from authorized CGMs, but the watch is not measuring glucose on its own.
The governance risks extend beyond clinical accuracy. CGM data can reveal patterns tied to food, sleep, stress, activity, and medication behavior. In the US, the FTC says many health apps and connected-device companies are not covered by HIPAA, though other consumer protection rules may still apply.
Regulators are also formalizing CGM data as trial evidence. In May 2026, the FDA issued guidance on technical specifications for submitting CGM data from clinical trials supporting drug and biologic marketing applications.
Enterprise buyers should ask whether the model was validated on real-world data, whether outcomes are clinical rather than model-only, how data is retained or used for training, and whether the product makes wellness, decision-support, or regulated medical claims. Higher-risk AI systems also need controls for monitoring, access, auditability, and shutdown.
CGM data is becoming machine-readable, but the strongest case remains narrow. Forecasting is credible; broader health profiling still needs stronger validation, representative data, and governance that can keep pace.
Also read: AI systems are moving from dashboards into physical environments, where safety, oversight, and deployment limits become harder to ignore.